AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteVX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageVX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageVX-702 is an orally bioavailable inhibitor of p38 MAP kinase that inhibits platelet agonist induced p38 activation (IC50= 4 to 20 nM).
More Information Supplier PageVX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38??, p38??and p38?? .
More Information Supplier PageVX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38??, p38??and p38?? .
More Information Supplier PageVX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38??, p38??and p38?? .
More Information Supplier PageVX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38??, p38??and p38?? .
More Information Supplier PageVX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38??, p38??and p38?? .
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageWalrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator.
More Information Supplier PageWalrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator.
More Information Supplier PageWalrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator.
More Information Supplier PageWAY 170523 has been reported to be a selective and potent inhibitor of MMP-13.
More Information Supplier PageWAY 170523 has been reported to be a selective and potent inhibitor of MMP-13.
More Information Supplier PageWAY-100635 was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor.
More Information Supplier PageWAY-100635 was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor.
More Information Supplier PageWAY-100635 was originally believed to act as a selective 5-HT1A receptor antagonist, but subsequent research showed that it also acts as potent full agonist at the D4 receptor.
More Information Supplier PageWAY-100635 maleate is a potent and selective 5-hydroxytryptamine1A antagonist with an IC50 of 0.95 – 0.12 nM for 5-HT.
More Information Supplier PageWAY-100635 maleate is a potent and selective 5-hydroxytryptamine1A antagonist with an IC50 of 0.95 – 0.12 nM for 5-HT.
More Information Supplier PageWAY-100635 maleate is a potent and selective 5-hydroxytryptamine1A antagonist with an IC50 of 0.95 – 0.12 nM for 5-HT.
More Information Supplier PageWAY-316606 is a small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt.
More Information Supplier PageWAY-316606 is a small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt.
More Information Supplier PageWAY-316606 is a small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt.
More Information Supplier PageWAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).
More Information Supplier PageWAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).
More Information Supplier PageWAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).
More Information Supplier PageWAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).
More Information Supplier PageWAY-362450 is a highly potent, selective, and orally bioavailable farnesoid X receptor (FXR) agonist (EC50: 4 nM, eff=149%).
More Information Supplier PageWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
More Information Supplier PageWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
More Information Supplier PageWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
More Information Supplier PageWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
More Information Supplier PageWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
More Information Supplier PageWedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1?? maturation and pathological apoptosis.
More Information Supplier PageWedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1?? maturation and pathological apoptosis.
More Information Supplier PageWedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1?? maturation and pathological apoptosis.
More Information Supplier PageWF-11899A is a novel antifungal lipopeptide antibiotics were isolated from the culture broth of Coleophoma empetri F-11899
More Information Supplier Page
